NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

Lykiri,

Really good find! I have said for a while that I believed that the wait we have endured is at least partially related to comparing German data with data from the rest of the trial. I came to the conclusion that the Germans became convinced that at least the low absolute lymphocyte patients were responding, perhaps with pseudoprogression, and then perhaps finding total clearing of the tumor in some of the patients. Since patients were not being screened by tumor subtype, and certain subtypes were perhaps obviously responding very well, then the Germans would not allow any SOC/placebo patients into the trial knowing that a statistically significant correlation existed. Is it just a coincidence that IDH-1 status has been added in at the end of this trial or that mesenchymal patients might tend to do better than normal? The science tells me no and the "screening hold" might just be in support of the science ie good news turned into bad. Best wishes.